Other
All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC
Abstract
Extensive-disease SCLC (ED-SCLC) is a recalcitrant disease. There had been no new therapies for more than three decades and no improvement in patient outcomes until the introduction of immune checkpoint inhibitors (ICIs) in the first-line setting. These agents, atezolizumab and durvalumab, have modestly improved the survival of the patients with ED-SCLC.1,2 For a previously treated population, topotecan, amrubicin (approved in Japan), and...
Paper Details
Title
All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC
Published Date
Sep 1, 2021
Journal
Volume
16
Issue
9
Pages
1429 - 1433
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History